Third triMSx webcast

COVID-19 and MS: where are we now and where next?

The third triMSx webcast, 8 and 9 April 2021

19:00-19:45 BST | 14:00-14:45 EDT | 20:00-20:45 CEST

  • COVID-19 vaccination rates and country-specific examples
  • Dosage and timing of vaccination for people with MS receiving a DMT
  • Vaccine hesitancy: how can we encourage confidence within the MS community?
  • COVID-19 and global MS registries: latest data

 

 

triMS.online would like to acknowledge Merck KGaA, Darmstadt, Germany for providing an independent medical education grant for this triMSx event

MERCK VIB_M_ORG_1_RbVyVm_RGB for website

About this event

The COVID-19 pandemic continues and questions remain. How can we best support our patients with MS in the current climate?
Are we equipped to provide our patients with reliable and evidence-based information about vaccines and vaccination programmes?
Our third triMSx event will address the following topics.

  • COVID-19 vaccination rates and country-specific examples.
  • Dosage and timing of vaccination for people with MS receiving a DMT.
  • Vaccine hesitancy: how can we encourage confidence within the MS community?
  • COVID-19 and global MS registries: latest data.

This triMSx webinar, a free educational initiative linked to triMS.online, provides an opportunity for the global MS community to share knowledge on issues that are currently affecting the day-to-day management of patients living with MS.

free-registration

Day 1

Video

Chapters

00:00:00 Welcome
Gavin Giovannoni, UK
00:04:03 COVID-19 vaccines – a race against time
Ron Milo, Israel
00:13:27 COVID-19 vaccines and DMTs – vaccine readiness in MS
Celia Oreja-Guevara, Spain
00:22:51 COVID-19 and MS registries – what we know now
Liesbet Peeters, Belgium
00:31:13 Q&A
00:52:54 Meeting close
Gavin Giovannoni, UK

Day 2

Video

Chapters

00:00:00 Welcome
Gavin Giovannoni, UK
00:03:21 Case study 1: DMTs and vaccination timing
Klaus Schmierer, UK
00:09:43 Case study 1: Q&A
00:18:12 Case study 2: prioritizing patients with MS
Dimitrios Karussis, Israel
00:24:55 Case study 2: Q&A
00:32:29 Case study 3: tackling vaccine hesitancy in patients with MS
Hollie Schmidt, USA
00:39:58 Case study 3: Q&A
00:53:40 Meeting close
Gavin Giovannoni, UK

Scientific programme

8 April
19:00–19:45

Where are we now and where next?

Welcome

Gavin Giovannoni, UK

COVID-19 vaccines – a race against time

Ron Milo, Israel

COVID-19 vaccines and DMTs – vaccine readiness in MS Celia

Oreja-Guevara, Spain

COVID-19 and MS registries – what we know now

Liesbet Peeters, Belgium

Q&A

Meeting close

Gavin Giovannoni, UK

9 April
19:00–19:45

Patient case studies

Welcome

Gavin Giovannoni, UK

Case study 1: DMTs and vaccination timing

Klaus Schmierer, UK

Case study 2: prioritizing patients with MS

Dimitrios Karussis, Israel

Case study 3: tackling vaccine hesitancy in patients with MS

Hollie Schmidt, USA

Meeting close

Gavin Giovannoni, UK
Register

Resources

Where are we now and where next - Q&As

0.38MB PDF